Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Biliary Tract Neoplasms × durvalumab × Clear all

Phase

Status

Recruiting 14 Completed 5 Active not recruiting 5 Unknown 3 Withdrawn 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 6 Triple Negative Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Pancreatic Neoplasms 3 Colorectal Neoplasms 3 Urinary Bladder Neoplasms 2 Carcinoma, Renal Cell 2 Uveal Melanoma 1 Squamous Non-small Cell Lung Cancer 1 Small Cell Lung Carcinoma 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Oropharyngeal Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Microsatellite Instability 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large B-Cell, Diffuse 1 Liver Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Breast Cancer Female 1 Biliary Tract Neoplasms 1 Adenocarcinoma of Lung 1 Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 3 Cisplatin 3 Irinotecan 2 Fluorouracil 2 Capecitabine 2 tremelimumab 1 pamiparib 1 durvalumab 1 brigimadlin 1 atezolizumab 1 Temozolomide 1 Surgical Procedures, Operative 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 IMC-001 1 Blood Specimen Collection 1 ARX788 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06017297 2024-11-12

ESR-22-21719

Georgetown University

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡